CLINICAL STAGE III HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8
Clinical trials for CLINICAL STAGE III HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new CLINICAL STAGE III HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for CLINICAL STAGE III HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo therapy aims to boost survival in head and neck cancer
Disease control Recruiting nowThis phase II trial tests whether adding chemotherapy or chemo-immunotherapy before standard salvage surgery helps patients with recurrent or persistent head and neck cancer. About 180 participants with PD-L1 positive tumors will receive either carboplatin and paclitaxel, or thos…
Matched conditions: CLINICAL STAGE III HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 23, 2026 19:31 UTC
-
Blood test could help throat cancer patients get less radiation
Disease control Recruiting nowThis phase II trial tests whether a blood test that detects HPV DNA can help doctors decide the right amount of radiation for people with HPV-positive throat cancer. About 455 participants will either have surgery or receive standard chemotherapy plus radiation, but the radiation…
Matched conditions: CLINICAL STAGE III HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 23, 2026 11:56 UTC
-
Biomarker-Guided combo aims to outsmart resistant cancers
Disease control Recruiting nowThis phase II trial is testing whether the combination of cabozantinib (a targeted drug) and nivolumab (an immunotherapy) can shrink or stabilize advanced melanoma and head/neck cancers that have stopped responding to prior immunotherapy. Researchers will also see if two tumor bi…
Matched conditions: CLINICAL STAGE III HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 22, 2026 11:58 UTC
-
New drug combo aims to boost chemoradiation for head and neck cancer
Disease control Recruiting nowThis early-phase study tests whether adding the experimental drug ipatasertib to standard chemotherapy and radiation is safe and effective for people with advanced head and neck cancer. Ipatasertib may help stop cancer cell growth. About 46 participants will receive the combinati…
Matched conditions: CLINICAL STAGE III HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 18, 2026 11:50 UTC
-
New drug plus precision radiation aims to tame recurrent head and neck cancer
Disease control Recruiting nowThis early-stage trial tests a drug called camonsertib combined with precise radiation for head and neck cancer that has returned or cannot be surgically removed. The study aims to find the safest dose and see if the combination can control tumor growth. About 39 adults with cert…
Matched conditions: CLINICAL STAGE III HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 12, 2026 12:07 UTC
-
New drug aims to prevent painful mouth sores in head and neck cancer treatment
Symptom relief Recruiting nowThis study tests whether adding BMX-001 to standard care can reduce severe mouth sores caused by chemoradiation in head and neck cancer patients. About 98 participants will receive either BMX-001 or a placebo alongside usual mouth rinses and pain medications. The goal is to impro…
Matched conditions: CLINICAL STAGE III HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: NRG Oncology • Aim: Symptom relief
Last updated Jun 15, 2026 18:57 UTC
-
Can blood tests predict who will do their swallowing exercises?
Knowledge-focused Recruiting nowThis study looks at why people with head and neck cancer follow (or don't follow) swallowing exercises after radiation. Researchers will use blood tests and questionnaires to see if immune system proteins or feelings about the disease affect exercise habits. The goal is to find w…
Matched conditions: CLINICAL STAGE III HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 22, 2026 12:08 UTC
-
Mayo clinic hunts for blood test to spot throat cancer early
Knowledge-focused Recruiting nowThis study looks for biological markers (biomarkers) in blood, tissue, and saliva that can show when HPV-related throat cancer is present or gone. Researchers will compare samples from 560 people with and without the cancer. The goal is to improve how doctors diagnose and track t…
Matched conditions: CLINICAL STAGE III HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 18, 2026 11:57 UTC
-
New imaging study aims to spot radiation damage to neck arteries
Knowledge-focused Recruiting nowThis study looks at how radiation therapy for head and neck cancers affects the blood vessels in the neck. Researchers will use two types of PET/CT scans to compare images taken before and after treatment. The goal is to better understand and detect radiation-related vascular dam…
Matched conditions: CLINICAL STAGE III HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8
Phase: EARLY_PHASE1 • Sponsor: Emory University • Aim: Knowledge-focused
Last updated Jun 17, 2026 12:07 UTC